Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label rollover extension of iptacopan in adults with primary IgA nephropathy
MOH_2021-08-16_010206Phase 3Recruiting
- Sponsor
- Novartis
- Start
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of Iptacopan in IgA nephropathy (IgAN), sponsored by Novartis. Primary endpoint: Long-term safety and tolerability of iptacopan. Started Aug 2021; status: recruiting.
02
Drugs
Iptacopan
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on MOH_2021-08-16_010206.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-08-16_010206.